Cresco Spine has received FDA 510(k) clearance for the Spring Distraction System (SDS™), marking a significant milestone in the regulatory and clinical journey of this growth-friendly implant developed for the treatment of early onset scoliosis (EOS).This clearance is not an isolated achievement. It represents the outcome of a long, disciplined, and highly collaborative regulatory process.
From Breakthrough Designation to Clearance
Earlier in its regulatory trajectory, SDS™ received FDA Breakthrough Device Designation, a status reserved for technologies addressing serious or life-threatening conditions where meaningful clinical improvement is anticipated. Since the program was introduced by the U.S. Food and Drug Administration in 2015, only a very small fraction of devices that ultimately proceed through the 510(k) pathway have received this designation. Fewer than 0.1 percent reach this combination of recognition and clearance, underscoring both the substantial unmet need in EOS and the potential clinical impact of SDS™.
What ultimately proved most important, however, was the work that followed.
A Structured and Collaborative Regulatory Journey
In close collaboration with its R&D and regulatory partner BAAT Medical, and through continuous engagement with the FDA review team, Cresco Spine pursued a structured regulatory approach built around focused regulatory sprints, clearly defined questions, and well-articulated deliverables. Early alignment on what constituted a complete and high-quality submission was a critical success factor.
The process was rigorous, constructive, and transparent. It required discipline, precision, and sustained collaboration across teams. This was not an effort driven by shortcuts, but a deliberate commitment to regulatory quality and integrity.
From Clearance to Clinical Impact
With FDA clearance secured, Cresco Spine will initiate a controlled clinical release of SDS™ in a limited number of leading pediatric hospitals in the United States and Canada. This phased introduction is designed to support careful clinical adoption and to ensure that early experience outside the Netherlands is grounded in high-quality training, structured follow-up, and robust outcome monitoring.
For the first time, children with EOS in these regions will be treated with SDS™ as part of a carefully managed rollout strategy.
Scaling Access, Responsibly
In parallel with the initial North American release, Cresco Spine remains committed to scaling access responsibly and sustainably. Australia and New Zealand represent the next regions on the geographic roadmap, reflecting strong clinical interest and alignment with the company’s broader regulatory strategy.
Europe remains equally important. The CE marking process is ongoing under the orphan pathway, with the objective of making SDS™ available to children with early onset scoliosis across Europe as soon as possible.
The Mission Ahead
SDS™ was developed to reduce treatment burden during growth and to respect spinal physiology in children affected by EOS. While FDA 510(k) clearance represents a major regulatory milestone for Cresco Spine, it is not the endpoint.
The mission remains clear:
to enable worldwide access to SDS™ for children with early onset scoliosis, delivered responsibly, rigorously, and with clinical integrity.
About Cresco Spine
Cresco is developing Dynamic Implant Solutions™, a line of dynamic implant systems to treat scoliosis. Specifically, the dream is to establish new standards for surgical treatment of pediatric spinal deformities based on these dynamic implants. We strive to improve the treatment of children and adolescents with severe spinal deformities.Website: www.cresco-spine.com